Search Results

You are looking at 51 - 60 of 391 items for :

  • Refine by Access: All x
Clear All
Full access

QIM24-181: Joining Forces to Minimize Hypomagnesemia in Patients Receiving Cisplatin and Cetuximab Infusions

Janice DallaCosta, Patrick Skeffington, and Ny Tran

complete. Unfortunately, the symptoms of hypomagnesemia mimic the side effects that patients experience when on these treatments; nausea, vomiting, poor appetite, weakness, fatigue, muscle cramps and confusion. This can lead to misdiagnosis and treatment

Full access

JNCCN CE Offerings

CME/CE articles published in previous issues of JNCCN: Corticosteroids in the Treatment of Chemotherapy-Induced Nausea and Vomiting Expiration Date: 4/9/13 Update on Safety of ESAs in Cancer-Induced Anemia Expiration Date: 5

Full access

Cancer, Cannabis, and the Search for Relief

Marcin Chwistek

-reported a higher severity of pain, nausea, and insomnia, and worse overall and spiritual well-being compared with those who did not have positive UDT results. The use of cannabis in this group may be related to a number of factors. The authors postulated

Full access

CLO22-046: A Prospective Study Comparing Acute Toxicities With Three Dimensional Conformal Radiation Therapy versus Intensity Modulated Radiation Therapy in Carcinoma Cervix Patients at a Tertiary Cancer Center

Syeda Tahera Fatima and K. Prakash

weekly for cystitis, dermatitis, enteritis (nausea/vomiting, diarrhea, enterocolitis) and hematological toxicity with weekly CBP according to CTCAE criteria. Statistical analysis : Statistical analysis will be done with chi squared tests with p value

Full access

CRE24-049: Extrapulmonary Small Cell Carcinoma of Gallbladder Presenting as Acute Cholecystitis

Cindy Iwuagwu, Sesha Sai Kanakamedala, Sarah Tinsley, and Jamal Mohsin

, providing limited opportunities for intervention. Case Description: A 74-year-old male presented to the emergency department, complaining of subacute right upper quadrant pain, nausea, and vomiting. He was hemodynamically stable with a positive Murphy

Full access

HSR24-149: Mobile Health (mHealth) Interventions for Colorectal Cancer (CRC) Survivors: A Systematic Review

Cheongin Im, Megan C. Thomas Hebdon, Namuun E Clifford, and Carolyn Phillips

); Fitbit (n=3); mobile apps only (n=3); phone and virtual networks (n=1); and WeChat (n=1). The primary outcomes were physical activity (n=5); QoL (n=3); nutrition (n=1); physical side effects (eg, nausea, vomiting, peripheral neuropathy) (n=2

Full access

CLO20-041: Prognostic Factors in Major Salivary Gland Tumors Treated with Adjuvant Radiation Therapy

Jung Julie Kang, Hannah Verma, Kaveh Zakeri, Huili Wang, Dan Fan, Ming Fan, Anna Lee, Sarin Kitpanit, Linda Chen, Yao Yu, C. Jillian Tsai, Sean McBride, Nadeem Riaz, Daphna Gelblum, Alan S. Ho, Eric Sherman, Lara Dunn, Jay O. Boyle, Richard J. Wong, Ian Ganly, and Nancy Y. Lee

experienced acute Grade 3 toxicity (hospitalization for nausea/vomiting) and two patients experienced late Grade 3 toxicity (osteoradionecrosis of the temporal bone and osteoradionecrosis of the mandible, both requiring surgical interventions). No early or

Full access

HSR20-112: Quantifying Caregiver Preferences for Attributes Associated With First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

Candice Yong, Brian Seal, M. Janelle Cambron-Mellott, Oliver Will, Martine C. Maculaitis, Kelly Clapp, Emily Mulvihill, Ion Cotarla, and Ranee Mehra

( Figure 1 ). To accept an increase in risk of a Grade 3/4 AE from 18% to 70%, all grades nausea from 10% to 69%, skin rash from 12% to 22%, and pneumonitis from <1% to 8%, OS would need to increase by 17, 4, 1.5, and 0.4 months, respectively. Most CGs (72

Full access

HSR22-154: Treatment Patterns Following Osimertinib Discontinuation in Patients With EGFR Mutated Metastatic NSCLC

Elizabeth Marrett, Winghan Jacqueline Kwong, Jinlin Song, Ameur M. Manceur, Selvam Sendhil, and Eric Wu

/pneumonitis (3.0), infection/sepsis (2.1), nausea and vomiting (1.9), fever (1.7), and diarrhea (1.5). Conclusions : After osimertinib discontinuation, plat-chemo regimens were the most common subsequent LOT, followed by reuse of EGFR-TKIs. Overall, the

Full access

NCCN News

Therapies Wednesday, March 28, 2018 • 5:00–6:00 PM EDT Richard L. Fong, PharmD, BCOP, UCSF Helen Diller Family Comprehensive Cancer Center New Agents for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting Monday, April 16, 2018